



Sterigenics Issues Statement on Final NESHAP Regulations

Significant, proactive investments in state-of-the-art enhancements in Sterigenics' EtO facilities have positioned the Company well for compliance with very challenging new rule.

We are pleased that the Environmental Protection Agency (EPA) has finalized the updated National Emission Standards for Hazardous Air Pollutants (NESHAP) regulations after years of consultation with other government agencies, state and local regulators, NGO's, the healthcare industry and other stakeholders. The final NESHAP revisions reflect EPA's commitment to safeguarding communities while accounting for the potential impact to the safe and reliable supply of sterile medical equipment to the healthcare industry and the millions of patients who depend on this supply. It will be important for the EPA to continue to engage constructively with all stakeholders in finalizing the FIFRA rules later this year.

Sterigenics remains fully committed to our mission of Safeguarding Global Health®. We continue to disagree with the EPA's assessment of the carcinogenicity of low-level emissions of ethylene oxide (EtO) and we anticipate the updated NESHAP requirements will be very challenging for the sterilization industry to meet. However, upon our initial review of the new regulations, we believe that Sterigenics' significant investments across our EtO facilities in permanent total enclosure (PTE) technology that meets EPA Method 204 and other state-of-the-art facility enhancements have positioned Sterigenics to be able to comply with the updated requirements within the timeframes specified by the final rule.

Our employees are proud of our industry leadership on safety. As we have consistently demonstrated throughout our history, we will operate in compliance with applicable rules and regulations and otherwise cooperate with our regulators to ensure the safety of our employees, the communities in which we operate and patients around the world.

Updates on recent developments in matters relevant to investors can be found on the Investor Relations section of the Sotera Health website at [Investor Relations | Sotera Health](#). For developments related to EtO, updates can be found at [Ethylene Oxide | Sotera Health](#).

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements that reflect our expectations about future events and our operating plans and performance and speak only as of the date hereof. You can identify these forward-looking statements by the use of forward-looking words such as "will," "be able," "plan," "anticipate," "committed," "believe," "positioned," or the negative versions of those words or other comparable words. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, are forward-looking statements. Any forward-looking statements contained in this release are based upon our historical performance and on our current plans, estimates and expectations. The inclusion of this forward-looking information should not be regarded as a representation by us that the future plans, estimates or expectations contemplated by us will be achieved. These forward-looking statements are subject to various risks, uncertainties and assumptions relating to our operations, financial results, financial condition, business, prospects, growth strategy and liquidity. These risks and uncertainties include, without limitation, any disruption in the availability or supply of, or increases in the price of EtO; changes in industry trends, environmental, health and safety regulations or preferences, and general economic, social and business conditions; the impact and outcome of current and future legal proceedings and liability claims, including litigation related to EtO regulation, use of EtO and/or emission and releases of EtO from our facilities in



Illinois, Georgia and New Mexico and the possibility that other claims will be made in the future relating to these or other facilities. For additional discussion of these risks and uncertainties, please refer to the Company's filings with the SEC, such as its annual and quarterly reports. We do not undertake any obligation to publicly update or revise these forward-looking statements, except as otherwise required by law.

About Sterigenics

Sterigenics is a leading global provider of outsourced terminal sterilization services for the medical device, pharmaceutical, food safety and advanced applications markets. With our industry recognized expertise, we help to ensure the safety of millions of patients around the world every year. Across our 48 global facilities, we offer our customers a complete range of sterilization services, primarily using the three major technologies: gamma irradiation, ethylene oxide processing and electron beam irradiation. We are committed to addressing the growing need for sterilization across the world.

INVESTOR RELATIONS CONTACTS

Jason Peterson

Vice President & Treasurer, Sotera Health

IR@soterahealth.com

MEDIA CONTACT

Kristin Gibbs

Chief Marketing Officer, Sotera Health

kgibbs@soterahealth.com

###